• share
• favorite_border

Memorial Sloan Kettering Cancer Center (MSK) announces its most recent awards and appointments for the institution’s physicians, scientists, nurses, and staff.

• share
• favorite_border

Combined therapy may improve clinical responses for endometrial, colorectal and gastric tumors. Enzyme inhibitor with anti-PD1 checkpoint blockade boosted efficacy over either treatment alone

• share
• favorite_border

Cancer care providers will gather in Orlando on March 20-22 for the National Comprehensive Cancer Network® (NCCN®) 2020 Annual Conference: Celebrating 25 Years of NCCN. The three-day, in-person conference features more than 30 educational sessions on state-of-the-art practices in cancer care.

• share
• favorite_border

To date, work done within the Tri-I TDI has resulted in the launch of two New York City–based companies and the licensing of six therapeutic discovery programs.

• share
• favorite_border

The University of Kansas Cancer Center has partnered with Fox4 and the Kansas City Kansas School district to host a town hall on vaping at Sumner Academy February 27.

• share
• favorite_border

Cognitive processing in people with intellectual disability can now be accurately assessed thanks to UC Davis Health researchers who updated and validated series of tests, part of the NIH Toolbox Cognitive Battery.

• share
• favorite_border

Comprehensive profiling of tumor samples taken from patients with osteosarcoma shows that multiple factors contribute to the traditionally poor responses observed from treatment with immune checkpoint inhibitors, according to new research from The University of Texas MD Anderson Cancer Center.

• share
• favorite_border

MD Anderson announces a strategic research collaboration with Denali Therapeutics to develop new targeted therapies for Alzheimer's and other neurodegenerative diseases.

• share
• favorite_border

According to the results of a large, global study led by Yale Cancer Center researchers, even a tiny amount of a biomarker known as PD-L1 (programmed death-ligand1) can predict a long-term survival benefit from using pembrolizumab (Keytruda).

• share
• favorite_border

Research from Rutgers Cancer Institute of New Jersey shows administering the immunotherapy drug pembrolizumab together with chemotherapy given at the same time as radiation treatment (chemoradiation) is safe and tolerable as a first-line therapy for patients with stage 3 non-small cell lung cancer (NSCLC).